Louise Chen
Stock Analyst at Cantor Fitzgerald
(3.04)
# 1,361
Out of 4,711 analysts
284
Total ratings
40.44%
Success rate
0.98%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRO Spero Therapeutics | Reiterates: Overweight | n/a | $0.96 | - | 5 | Nov 15, 2024 | |
| NVO Novo Nordisk | Reiterates: Overweight | $160 | $85.00 | +88.24% | 20 | Nov 6, 2024 | |
| PCVX Vaxcyte | Reiterates: Overweight | n/a | $86.53 | - | 6 | Nov 6, 2024 | |
| PFE Pfizer | Reiterates: Overweight | $45 | $26.36 | +70.71% | 30 | Oct 25, 2024 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $26.72 | - | 7 | Oct 25, 2024 | |
| JNJ Johnson & Johnson | Reiterates: Overweight | $215 | $144.47 | +48.82% | 40 | Oct 16, 2024 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | n/a | $8.49 | - | 5 | Oct 11, 2024 | |
| MRK Merck & Co. | Reiterates: Overweight | $155 | $98.05 | +58.08% | 25 | Oct 3, 2024 | |
| ROIV Roivant Sciences | Reiterates: Overweight | n/a | $11.57 | - | 9 | Sep 19, 2024 | |
| LLY Eli Lilly | Reiterates: Overweight | $885 | $767.76 | +15.27% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.89 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $25.86 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.63 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.18 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $23.22 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $175.58 | +13.91% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.84 | - | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.96 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.82 | - | 4 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.16 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.46 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.65 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $701.85 | +31.79% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.00 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $11.56 | +462.28% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.72 | - | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.95 | +425.82% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $0.92 | +2,608.56% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $14.31 | +249.41% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $14.99 | +233.56% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.11 | +350.45% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $2.50 | +260.00% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $21 | $0.36 | +5,673.99% | 3 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $67,500 | $0.93 | +7,293,254.94% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $483.52 | -46.64% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $22.09 | -32.10% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.58 | +3,064.56% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.54 | +1,198.70% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $3.09 | +1,518.12% | 1 | Jul 21, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $4.68 | +861.54% | 1 | Jun 22, 2017 |
Spero Therapeutics
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.96
Upside: -
Novo Nordisk
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $85.00
Upside: +88.24%
Vaxcyte
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $86.53
Upside: -
Pfizer
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $26.36
Upside: +70.71%
Zai Lab
Oct 25, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.72
Upside: -
Johnson & Johnson
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $144.47
Upside: +48.82%
Zevra Therapeutics
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.49
Upside: -
Merck & Co.
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $98.05
Upside: +58.08%
Roivant Sciences
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.57
Upside: -
Eli Lilly
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $767.76
Upside: +15.27%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.89
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $25.86
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.63
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.18
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $23.22
Upside: -
Aug 5, 2024
Reiterates: Overweight
Price Target: $200
Current: $175.58
Upside: +13.91%
Aug 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.84
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.96
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.82
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.16
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.46
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.65
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $701.85
Upside: +31.79%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.00
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $11.56
Upside: +462.28%
Nov 14, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.72
Upside: -
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $0.95
Upside: +425.82%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $0.92
Upside: +2,608.56%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $14.31
Upside: +249.41%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $14.99
Upside: +233.56%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.11
Upside: +350.45%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $2.50
Upside: +260.00%
May 10, 2023
Maintains: Neutral
Price Target: $33 → $21
Current: $0.36
Upside: +5,673.99%
Jul 7, 2021
Initiates: Overweight
Price Target: $67,500
Current: $0.93
Upside: +7,293,254.94%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $483.52
Upside: -46.64%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $22.09
Upside: -32.10%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.58
Upside: +3,064.56%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.54
Upside: +1,198.70%
Jul 21, 2017
Initiates: Overweight
Price Target: $50
Current: $3.09
Upside: +1,518.12%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $4.68
Upside: +861.54%